We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




High Sensitivity Blood Test Aids Emergency Diagnosis of Heart Conditions

By LabMedica International staff writers
Posted on 29 Nov 2023

Troponin, a protein released into the bloodstream during heart attacks or other heart injuries, has long been a focal point in medical diagnostics. More...

Traditionally, various troponin blood tests have aided doctors in diagnosing heart conditions, especially in individuals experiencing chest pain and similar symptoms. Now, researchers have discovered a new method of measuring troponin levels, offering the potential to reduce future heart attacks in high-risk patients by 10% over five years. This advanced test is distinguished by its heightened accuracy in detecting even minimal troponin levels in the bloodstream, surpassing the capabilities of older tests.

Researchers at the University of Edinburgh (Scotland, UK) conducted an extensive study to evaluate the effectiveness of this innovative test. They analyzed health data from nearly 50,000 individuals with a suspected heart attack who visited ten emergency departments across Scotland between 2013 and 2016. Using general health records, the team tracked these individuals over five years. The new test identified over 10,000 patients with elevated troponin levels, indicative of heart injury. Notably, this high-sensitivity test detected subtle warning signs, identifying about 20% of these cases, which would have been missed by traditional tests.

The most significant impact of the test was observed in patients with heart muscle injuries caused by other cardiac conditions, such as heart failure, valve issues, and arrhythmias. Analysis showed that these patients experienced nearly a 10% reduction in subsequent hospital admissions and mortality over the following five years when tested with the new method, compared to those who underwent the older, less sensitive testing. This advancement in detecting heart injuries, particularly in cases that might have previously been overlooked, could enable more patients to receive specialized cardiac care, potentially preventing more severe health incidents in the future.

“In the past, clinicians could have been falsely reassured by the results of the less sensitive troponin test, discharging patients that appeared to not have heart disease,” said Dr Ken Lee, Clinical Lecturer in Cardiology at the University of Edinburgh. “This new high sensitivity test is the tool they needed, prompting them to look deeper and helping them to identify and treat both heart attacks and less obvious heart problems. In our trial, introducing this test led to an impressive reduction in the number of future heart attacks and deaths seen in this at-risk group.”

“Medical professionals in emergency departments need the most efficient and accurate tools to look after people,” added Professor Sir Nilesh Samani, Medical Director at the British Heart Foundation, which funded the study. “This particularly applies to those who arrive with a suspected heart attack. Such a time-sensitive and life-threatening condition requires the very best diagnostic tests. It is very encouraging to see that the new test trialed here is better at predicting long-term outcomes for these patients, whether they had a heart attack or a different kind of heart injury. This can lead to improved care for such patients.”

Related Links:
University of Edinburgh 


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.